- The report primarily focuses on tracking and analyzing the performance of broad-based indices in the A-share market, including their daily returns, moving averages, turnover rates, and valuation metrics such as PE-TTM and dividend yield[2][3][14] - The turnover rate of the indices is calculated as the weighted average of the turnover rates of their constituent stocks, weighted by the free-float market capitalization of each stock[16] - The risk premium of the indices is measured relative to the yield of 10-year government bonds, serving as a reference for risk-free rates. This metric evaluates the relative investment value and deviation of the indices[26][27][29] - The PE-TTM (Price-to-Earnings Trailing Twelve Months) is used as a valuation reference to assess the investment value of the indices at the current point in time. The report highlights that the PE-TTM percentiles of indices like CSI 1000 (95.7%) and CSI 500 (94.88%) are relatively high, while those of CSI 300 (80.91%) and ChiNext (57.27%) are lower[36][39][40] - Dividend yield is analyzed as a measure of cash return, particularly relevant during market downturns. The report notes that ChiNext (67.6%) and CSI 1000 (49.59%) have relatively high 5-year historical percentiles, while CSI 500 (15.95%) and CSI 2000 (14.79%) are lower[45][49][51] - The report also tracks the percentage of stocks trading below their book value (PB ratio < 1), referred to as the "break-net ratio." This metric reflects market valuation attitudes, with lower ratios potentially indicating optimism about future growth. Current break-net ratios are reported as 20.0% for SSE 50, 15.67% for CSI 300, 11.8% for CSI 500, 8.2% for CSI 1000, 3.4% for CSI 2000, 1.0% for ChiNext, and 6.37% for CSI All Share[50][53]

Investment Rating - The industry rating is "Overweight" (maintained) [6] Core Viewpoints - The establishment of Beijing Guanghe Qiancheng Technology Co., Ltd., a national-level operation platform for polysilicon capacity integration and strategic storage, is expected to fundamentally change the competitive landscape of the polysilicon industry [6] - The main mission of this platform is to adjust and stabilize industry capacity and products through market-oriented methods, with mainstream polysilicon prices expected to stabilize above 60,000 RMB per ton [6] - Major photovoltaic companies are optimistic about profitability in 2026, as indicated by Longi Green Energy's employee stock ownership plan [6] Summary by Sections Industry Performance - In the past 12 months, the industry has shown a relative return of -9.36% over one month, 6.86% over three months, and 0.92% over twelve months, with absolute returns of -11.56%, 10.16%, and 15.84% respectively [3] Market Dynamics - The polysilicon market is entering a new phase characterized by "market-oriented operations + industry collaborative regulation" [6] - In November, domestic polysilicon production was approximately 114,900 tons, a significant decrease of 15.9% month-on-month, with expectations for December production to remain below 120,000 tons [6] Investment Recommendations - Suggested stocks to focus on include Tongwei Co., Daqo New Energy, TCL Zhonghuan, and Shuangliang Eco-Energy for supply-demand improvement [6] - For new technology routes in BC batteries, recommended stocks include Longi Green Energy, Aiko Solar, Dier Laser, Juhua Materials, and Boqian New Materials [6]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [5] Core Viewpoints - The release of the first version of the commercial health insurance innovative drug directory marks a significant reform in China's pharmaceutical payment system, providing a clear commercial outlook for high-value innovative drugs [5][8] - The directory includes 19 drugs, focusing on key areas such as oncology, rare diseases, and Alzheimer's disease, which will enhance the accessibility and market penetration of these products [5][8] - The policy direction clearly supports "true innovation," with a low selection rate of approximately 15.7%, highlighting the recognition of differentiated innovative products with significant clinical advantages [8] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -1.43% over the past month, -11.86% over the past three months, and -7.77% over the past year compared to the CSI 300 index [3] Key Events - The release of the dual directories on December 7, 2025, by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security is a pivotal moment for the pharmaceutical industry [5][8] Investment Highlights - The breakthrough in payment bottlenecks directly benefits high-value innovative drugs, such as CAR-T therapies, by significantly reducing patient out-of-pocket expenses through commercial insurance reimbursement [8] - The opening of the payment side not only benefits pharmaceutical companies but also stimulates product innovation demand in commercial health insurance and drives research and production service needs in cutting-edge fields like cell and gene therapy [8] - Recommended companies include those with significant products included in the new national medical insurance directory or the commercial health insurance innovative drug directory, as well as leading biotech firms in the CAR-T field [8]

Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The report highlights the increasing significance of domestic AI chips in the electronics industry, with various companies launching innovative products such as AI glasses and mobile assistants [4][6] - The report emphasizes the rapid growth and adoption of AI edge devices, suggesting a focus on related companies like Alibaba, Xiaomi, Hengxuan Technology, and others [6] Summary by Sections Recent Industry Performance - The industry has shown relative returns of 0.82% over the past month, 10.46% over three months, and 30.55% over the past year compared to the CSI 300 index [3] Key Events - Alibaba launched the Quark AI glasses on November 27, 2025, featuring advanced technology and integration with various Alibaba services [5] - ByteDance introduced the Doubao mobile assistant on December 1, 2025, which can perform complex tasks like a human [5] - Huawei released the AI toy "Hanhai" on November 28, 2025, designed for emotional companionship [5] Investment Recommendations - The report suggests monitoring the growth of AI edge devices and related companies, indicating a positive outlook for the sector [6]

- The report does not include any quantitative models or factors for analysis or construction[1][2][3] - The content primarily focuses on market performance, index comparisons, turnover rates, risk premiums, PE-TTM, dividend yields, and net-breaking rates of various broad-based indices[1][2][3] - No quantitative models or factors are explicitly mentioned or analyzed in the provided content[1][2][3]

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Views - The company has undergone a strategic transformation from a single focus on orthopedics to multiple therapeutic areas including cardiovascular, nutritional supplements, and electrolyte regulation. The core strategy is centered around "product supremacy" through a "self-research + collaboration" model to enrich the product pipeline [6][14] - In the first half of 2025, the company achieved revenue of 1.0995 billion yuan, with nutritional drugs contributing 43.88% and cardiovascular drugs 27.99% to total revenue. The company has a stable shareholding structure with Shen Zhenyu as the actual controller [6][14] - The company has shown a gradual recovery in performance, with a net profit of 244 million yuan in Q3 2025, representing a year-on-year growth of 32.85%, establishing a healthy operating pattern characterized by low debt and high profitability resilience [6][14] Financial Performance - The company’s projected revenues for 2025-2027 are 2,252.80 million, 2,392.24 million, and 2,637.93 million yuan, with growth rates of -7.70%, 6.19%, and 10.27% respectively. The projected net profits for the same period are 254.40 million, 288.74 million, and 348.65 million yuan, with growth rates of 9.30%, 13.50%, and 20.75% respectively [7] - The current market capitalization corresponds to a PE ratio of 28.25 for 2025, 24.89 for 2026, and 20.61 for 2027, indicating a favorable valuation outlook as the company navigates the pressures of centralized procurement [6][7] Industry Analysis - The global pharmaceutical market is expected to reach 1.9 trillion USD by 2027, with China's market share anticipated to continue increasing. Innovative drug technologies such as ADC, bispecific antibodies, and CGT are projected to be core growth engines [6][14] - The industry is currently in a dual-track development phase characterized by the normalization of centralized procurement and supportive policies for innovative drugs. The company’s core products have a high market share and align well with industry trends, indicating strong adaptability [6][14]

Quantitative Models and Construction Barra Risk Model - **Model Name**: Barra Risk Model (Barra CNE6) - **Model Construction Idea**: The model aims to reduce the dimensionality of asset returns, enabling the calculation of covariance matrices between assets, which are essential for portfolio optimization. It uses constrained weighted least squares (WLS) to address multicollinearity and heteroscedasticity issues, constructing pure factor portfolios that isolate exposure to individual factors [3][9][11] - **Model Construction Process**: 1. The cross-sectional asset returns are modeled using a multi-factor linear regression: $R_{t}=\alpha+\beta\lambda_{t}+\varepsilon_{t}$ Here, $\beta$ represents factor exposures, $\lambda_{t}$ denotes factor returns, and $\varepsilon_{t}$ is the residual [9][10] 2. The covariance matrix of asset returns is derived as: $\Sigma_{R}=\beta\Sigma_{A}\beta^{T}+\Sigma_{E}$ $\Sigma_{A}$ is the covariance matrix of factors, and $\Sigma_{E}$ is the covariance matrix of residuals [11][12] 3. Factor exposures are standardized using market capitalization-weighted normalization: $$\widehat{\boldsymbol{\beta}_{t-1}^{j}}=\frac{{\boldsymbol{\beta}_{t-1}^{j}}-\frac{\sum_{i}^{N}s_{i,t-1}\beta_{i,t-1}^{j}}{\sum_{i}^{N}s_{i,t-1}}}{s t d({\boldsymbol{\beta}_{t-1}^{j}})}$$ Here, $s_{i,t-1}$ represents the market capitalization of stock $i$ at time $t-1$ [18][32] 4. Industry factor returns are constrained to ensure neutrality: $\sum_{i=1}^{P}s_{I_{i}}\lambda_{i}^{I_{i}}=0$ [18][22] 5. Factor returns are estimated using constrained WLS: $$\lambda_{t}=C_{t}(C_{t}\beta_{t-1}W^{-1}\beta_{t-1}C_{t})^{-1}C_{t}\beta_{t-1}W^{-1}R_{t}$$ Here, $W$ is the weight matrix, and $C_{t}$ represents constraints [20][25] - **Model Evaluation**: The model effectively isolates factor exposures, enabling better evaluation of factor returns. However, pure factor portfolios have low investability due to constraints like short-selling limitations [19][21] --- Quantitative Factors and Construction Style Factors - **Factor Names**: Size, Volatility, Liquidity, Momentum, Quality, Value, Growth, Dividend Yield - **Factor Construction Idea**: These factors represent different market characteristics, such as size, volatility, and growth, and are used to explain asset returns and identify systematic risks [3][15][26] - **Factor Construction Process**: 1. **Size**: Logarithm of market capitalization (LNCAP) [114] 2. **Volatility**: Includes Beta, historical sigma, daily standard deviation, and cumulative range [114] 3. **Liquidity**: Calculated using turnover ratios (monthly, quarterly, annual) and annualized traded value ratio [114] 4. **Momentum**: Includes short-term reversal, seasonality, industry momentum, and relative strength [114][115] 5. **Quality**: Includes earnings variability, accruals, profitability metrics, and investment quality [114][116] 6. **Value**: Includes book-to-price ratio, earnings-to-price ratio, and enterprise multiple [114][116] 7. **Growth**: Historical growth rates for earnings per share and sales per share [114][116] 8. **Dividend Yield**: Dividend-to-price ratio [114][116] - **Factor Evaluation**: Single-factor tests show limited stock selection ability, with low significance and effectiveness. However, after constructing pure factor models, the significance of factors improves, especially for Volatility and Momentum [66][78] Residual Factor - **Factor Name**: Residual Factor - **Factor Construction Idea**: Residuals represent the unexplained portion of stock returns after accounting for industry, style, and country factors. They are tested for nonlinear relationships with stock returns [79][82] - **Factor Construction Process**: 1. Residuals are derived from the regression model: $R_{t}=\beta_{t-1}C_{t}\gamma_{t}+\delta_{t}$ Here, $\delta_{t}$ represents residuals [23][79] 2. Residuals are used as stock selection factors and tested using layered backtesting [79][82] - **Factor Evaluation**: Residual factors exhibit strong nonlinear relationships with stock returns, showing robust stock selection ability. Middle-layer groups outperform top and bottom groups significantly [79][82] --- Backtesting Results Pure Factor Model - **Size**: Annualized return -2.75%, annualized volatility 0.026, maximum drawdown 35.53%, Sharpe ratio -1.08 [76][77] - **Volatility**: Annualized return 1.93%, annualized volatility 0.049, maximum drawdown 12.43%, Sharpe ratio 0.39 [76][77] - **Liquidity**: Annualized return -5.90%, annualized volatility 0.033, maximum drawdown 60.88%, Sharpe ratio -1.81 [76][77] - **Momentum**: Annualized return -5.57%, annualized volatility 0.042, maximum drawdown 58.64%, Sharpe ratio -1.32 [76][77] - **Growth**: Annualized return -0.21%, annualized volatility 0.015, maximum drawdown 9.24%, Sharpe ratio -0.15 [76][77] - **Dividend Yield**: Annualized return -0.85%, annualized volatility 0.016, maximum drawdown 17.09%, Sharpe ratio -0.52 [76][77] - **Quality**: Annualized return 0.35%, annualized volatility 0.016, maximum drawdown 8.45%, Sharpe ratio 0.23 [76][77] - **Value**: Annualized return 1.38%, annualized volatility 0.028, maximum drawdown 13.83%, Sharpe ratio 0.49 [76][77] Residual Factor - **Middle Layer (Group 5)**: Annualized return 17.98%, annualized volatility 26.94%, Sharpe ratio 0.68, maximum drawdown 52.50% [82] - **Top vs Bottom Layer (Group 5 vs Group 10)**: Excess annualized return 13.58%, excess Sharpe ratio 1.50 [82] --- Index Attribution Results Positive Excess Return Indices - **Indices**: CSI 500 (3.41%), ChiNext Index (18.23%) - **Key Drivers**: Small-cap, high volatility, low liquidity, high growth, low dividend yield styles; leading sectors include non-ferrous metals, electronics, communication, and new energy [101][110] Negative Excess Return Indices - **Indices**: CSI 1000 (-0.22%), CSI A500 (-1.60%), CSI 300 (-4.30%), SSE 50 (-10.27%) - **Key Drivers**: Large-cap, low volatility, high liquidity, low growth, high dividend yield styles; underperforming sectors include banking, non-bank finance, and food & beverage [101][110]

金融工程定期报告 证券研究报告·金融工程报告 2025 年 12 月 10 日 江海证券研究发展部 分析师：梁俊炜 执业证书编号：S1410524090001 A 股市场快照：宽基指数每日投资动 部下跌，其中中证 500（-0.71%）和上证 50（-0.71%）跌幅最大。当年涨跌情况， 创业板指（49.87%）涨幅最大，其次是中证 2000（33.25%）和中证 500（24.37%）， 中证 1000（23.88%）和中证全指（22.15%）涨幅缩小，而上证 50（11.67%）涨幅 最小。另外，创业板指连续四日连阳。 ◆均线比较：所有跟踪指数仍在 5、10 及 20 日均线之上。中证 1000 重新跌回 60 ◆资金占比与换手：2025 年 12 月 9 日, 中证 2000（25.43%）交易金额占比最高， 相关研究报告 日均线。市场持续震荡。 态 2025.12.09 A 股市场快照：宽基指数每日投资动 态 2025.12.08 A 股市场快照：宽基指数每日投资动 态 2025.12.05 其次是沪深 300（24.33%）和中证 1000（21.11%）。各宽基指数当前换手率分别为 中证 2000 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Insights - The gaming sector shows strong performance with leading companies demonstrating significant revenue generation, particularly Tencent and Century Huatong, which ranked first and second in global mobile game publisher revenue [3][4] - The number of domestic game licenses issued in 2025 has increased by 29.39% year-on-year, indicating a supportive regulatory environment for the gaming industry [4] - The gaming sector is characterized by strong cash flow, ongoing policy support, and deepening AI game development, making it an attractive investment opportunity [6] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -3.47% compared to the CSI 300 index, with an absolute return of 12.26% [2] Market Developments - In November 2025, 33 Chinese companies made it to the global top 100 mobile game publishers, collectively generating $1.95 billion, which accounts for 35.8% of the total revenue of the top 100 publishers [3] - The flagship game "Whiteout Survival" from Century Huatong contributed 54% of its revenue in November, with total earnings exceeding $3.8 billion [3] Regulatory Environment - The National Press and Publication Administration issued 1,532 domestic game licenses from January to November 2025, reflecting a 29.39% increase compared to the same period in 2024 [4]

- The report primarily focuses on tracking and analyzing the performance of broad-based indices in the A-share market, including their daily returns, moving averages, turnover rates, and valuation metrics such as PE-TTM and risk premiums[1][2][3] - The analysis highlights that all broad-based indices experienced gains on December 8, 2025, with the ChiNext Index (2.6%) and CSI 2000 (1.47%) showing the largest daily increases. For the year-to-date performance, the ChiNext Index (48.97%) recorded the highest growth, followed by CSI 2000 (33.97%) and CSI 500 (25.27%)[10][11] - All indices have surpassed their 5-day, 10-day, and 20-day moving averages, with CSI 1000 and CSI All Share also breaking above their 60-day moving averages. However, CSI 500 remains below its 60-day moving average, indicating a continued market recovery[14][15] - The turnover rates for December 8, 2025, were highest for CSI 2000 (4.34), followed by ChiNext Index (2.78) and CSI 1000 (2.47). The lowest turnover rates were observed for SSE 50 (0.26) and CSI 300 (0.61)[17] - The distribution of daily returns shows that the ChiNext Index has the largest negative kurtosis deviation, while CSI 1000 has the smallest. Similarly, the ChiNext Index exhibits the largest negative skewness, indicating a higher likelihood of extreme negative returns compared to other indices[23][25] - Risk premiums, calculated relative to the 10-year government bond yield, are highest for the ChiNext Index (2.60%) and CSI 2000 (1.46%), with their 5-year percentile ranks at 93.41% and 85.79%, respectively. In contrast, SSE 50 (0.57%) and CSI 300 (0.80%) have lower risk premiums and percentile ranks[27][31] - The PE-TTM ratios for broad-based indices show that CSI 1000 (97.52%) and CSI 500 (95.54%) have the highest 5-year percentile ranks, while CSI 2000 (84.3%) and the ChiNext Index (57.69%) are relatively lower. The ChiNext Index's 5-year percentile rank is below its danger threshold of 80%[39][43][44] - Dividend yields are highest for SSE 50 (3.30%) and CSI 300 (2.71%), while CSI 500 (1.37%) and CSI 2000 (0.75%) are the lowest. The ChiNext Index's 5-year historical percentile rank for dividend yield is relatively high at 66.69%[48][53][55] - The percentage of stocks trading below their book value (PB ratio < 1) is highest for SSE 50 (22.0%) and lowest for the ChiNext Index (1.0%), reflecting varying market valuation attitudes across indices[57]